Council on Graduate Medical Education, 89113-89114 [2016-29499]
Download as PDF
Federal Register / Vol. 81, No. 237 / Friday, December 9, 2016 / Notices
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box, and follow the prompts;
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
Submit written requests for single
copies of this guidance to the Division
of Drug Information, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10001 New
Hampshire Ave., Hillandale Bldg. 4th
Floor, Silver Spring, MD 20993–0002; or
the Office of Communication, Outreach
and Development, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 3128,
Silver Spring, MD 20993–0002. Send
one self-addressed adhesive label to
assist that office in processing your
requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the guidance document.
FOR FURTHER INFORMATION CONTACT:
Office of Compliance, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Silver Spring, MD
20993–0002, 301–796–3130,
drugtrackandtrace@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
mstockstill on DSK3G9T082PROD with NOTICES
I. Background
FDA is announcing the availability of
a guidance for industry entitled ‘‘Drug
Supply Chain Security Act
Implementation: Identification of
Suspect Product and Notification.’’ The
guidance addresses provisions in the
FD&C Act, as amended by the DSCSA
(Pub. L. 113–54). Section 202 of the
DSCSA adds section 582(h)(2) to the
FD&C Act (21 U.S.C. 360eee–1(h)(2)),
which requires FDA to issue guidance to
aid certain trading partners
(manufacturers, repackagers, wholesale
distributors, and dispensers) in
identifying a suspect product and
terminating notifications. The guidance
identifies specific scenarios that could
significantly increase the risk of a
VerDate Sep<11>2014
18:13 Dec 08, 2016
Jkt 241001
suspect product entering the
pharmaceutical distribution supply
chain, and provides recommendations
on how trading partners can identify
such product and determine whether
the product is a suspect product as soon
as practicable.
Beginning January 1, 2015, section
582 of the FD&C Act required trading
partners, upon determining that a
product in their possession or control is
illegitimate, to notify: (1) FDA and (2)
all immediate trading partners that they
have reason to believe may have
received the illegitimate product, not
later than 24 hours after making the
determination. Manufacturers are
additionally required under section
582(b)(4)(B)(ii)(II) of the FD&C Act to
notify FDA and any immediate trading
partners that the manufacturer has
reason to believe may possess a product
manufactured by (or purported to be
manufactured by) the manufacturer, not
later than 24 hours after the
manufacturer determines or is notified
by FDA or a trading partner that there
is a high risk that a product is
illegitimate. Section III.C of this
guidance, entitled ‘‘For Manufacturers:
High Risk of Illegitimacy Notification’’
and highlighted in grey, describes
notifications related to products that
pose a high risk of illegitimacy, and is
marked ‘‘for comment purposes only’’ to
provide an opportunity for comment
before it is finalized. The guidance also
addresses how trading partners should
notify FDA using Form FDA 3911. In
addition, in accordance with section
582(h)(2) of the FD&C Act, the guidance
sets forth the process by which trading
partners must terminate the
notifications using Form FDA 3911, in
consultation with FDA, regarding
illegitimate product and, for a
manufacturer, a product with a high risk
of illegitimacy, under section
582(b)(4)(B), (c)(4)(B), (d)(4)(B), and
(e)(4)(B) of the FD&C Act.
In the Federal Register of June 11,
2014 (79 FR 33564), FDA announced the
availability of a draft guidance entitled
‘‘Drug Supply Chain Security Act
Implementation: Identification of
Suspect Product and Notification.’’ FDA
has carefully considered the comments
received and made the following
changes in response to the comments:
Section C, ‘‘For Manufacturers: High
Risk of Illegitimacy Notifications,’’ on
pgs. 8–11 of the guidance, is a new
section added in response to comments
and questions received. In addition,
FDA made minor changes to the Form
FDA 3911 and to the instructions for
completing the form.
This guidance is being issued
consistent with FDA’s good guidance
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
89113
practices regulation (21 CFR 10.115).
The guidance represents the current
thinking of FDA on ‘‘Drug Supply Chain
Security Act Implementation:
Identification of Suspect Product and
Notification.’’ It does not establish any
rights for any person and, with the
exception of section IV.B, is not binding
on FDA or the public. You can use an
alternative approach if it satisfies the
requirements of the applicable statutes
and regulations.
II. Electronic Access
Persons with access to the Internet
may obtain the guidance at https://
www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm, https://
www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatory
Information/Guidances/default.htm, or
https://www.regulations.gov.
III. Paperwork Reduction Act of 1995
This guidance contains information
collection provisions that are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collection of information in
this guidance was approved under OMB
control number 0910–0806.
Dated: December 5, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–29588 Filed 12–8–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Council on Graduate Medical
Education
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice of charter renewal.
AGENCY:
HHS is hereby giving notice
that the Council on Graduate Medical
Education (COGME) has been renewed.
The effective date of the renewed
charter is September 30, 2016.
FOR FURTHER INFORMATION CONTACT: Dr.
Kennita Carter, Senior Advisor and
Designated Federal Official, Division of
Medicine and Dentistry, HRSA, HHS,
15M116, 5600 Fishers Lane, Rockville,
MD 20857. Phone: (301) 945–3505;
email: kcarter@hrsa.gov.
SUPPLEMENTARY INFORMATION: COGME is
authorized by section 762 (42 U.S.C.
294o) of the Public Health Service Act,
SUMMARY:
E:\FR\FM\09DEN1.SGM
09DEN1
89114
Federal Register / Vol. 81, No. 237 / Friday, December 9, 2016 / Notices
as amended. Except where otherwise
indicated, COGME is governed by
provisions of the Federal Advisory
Committee Act (5 U.S.C. App. 2), as
amended, which sets forth standards for
the formation and use of advisory
committees. In accordance with the
Federal Advisory Committee Act
(FACA), COGME was initially chartered
on September 30, 1996, and has been
renewed at appropriate intervals.
COGME provides advice to the
Secretary of HHS (Secretary) on a range
of issues including: The supply and
distribution of physicians in the United
States; current and future physician
shortages or excesses; issues relating to
foreign medical school graduates;
Federal policies related to the
previously listed topics, including
policies concerning changes in the
financing of medical education training;
and the development of performance
measures and longitudinal evaluation of
medical education programs. COGME’s
reports are submitted to the Secretary
and Chairmen and Ranking Members of
the Senate Committee on Health,
Education, Labor, and Pensions and the
House of Representatives Committee on
Energy and Commerce.
Renewal of the COGME charter
authorizes the Committee to operate
until September 30, 2018.
A copy of the COGME charter is
available on the COGME Web site at
https://www.hrsa.gov/advisory
committees/bhpradvisory/cogme/
index.html. A copy of the charter also
can be obtained by accessing the FACA
database that is maintained by the
Committee Management Secretariat
under the General Services
Administration. The Web site address
for the FACA database is https://
www.facadatabase.gov/.
Jason E. Bennett,
Director, Division of the Executive Secretariat.
[FR Doc. 2016–29499 Filed 12–8–16; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
mstockstill on DSK3G9T082PROD with NOTICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Proposed Collection: Public
Comment Request; Children’s
Hospitals Graduate Medical Education
Payment Program Application and
Full-Time Equivalent Resident
Assessment Forms
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
AGENCY:
VerDate Sep<11>2014
18:13 Dec 08, 2016
Jkt 241001
ACTION:
Notice.
In compliance with the
requirement for opportunity for public
comment on proposed data collection
projects (Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995),
HRSA announces plans to submit an
Information Collection Request (ICR),
described below, to the Office of
Management and Budget (OMB). Prior
to submitting the ICR to OMB, HRSA
seeks comments from the public
regarding the burden estimate, below, or
any other aspect of the ICR.
DATES: Comments on this ICR should be
received no later than January 9, 2017.
ADDRESSES: Submit your comments to
paperwork@hrsa.gov or mail the HRSA
Information Collection Clearance
Officer, Room 14N–39, 5600 Fishers
Lane, Rockville, MD 20857.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and draft
instruments, email paperwork@hrsa.gov
or call the HRSA Information Collection
Clearance Officer at (301) 443–1984.
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the
information request collection title for
reference.
Information Collection Request Title:
Children’s Hospitals Graduate Medical
Education Payment Program
Application and Full-Time Equivalent
Resident Assessment Forms OMB No.
0915–0247 Revision.
Abstract: The Children’s Hospitals
Graduate Medical Education (CHGME)
Payment Program was enacted by Public
Law 106–129, and reauthorized by the
CHGME Support Reauthorization Act of
2013 (Pub. L. 113–98) to provide
Federal support for graduate medical
education (GME) to freestanding
children’s hospitals. The legislation
indicates that eligible children’s
hospitals will receive payments for both
direct and indirect medical education.
The CHGME Payment Program
application and full-time equivalent
(FTE) resident assessment forms
received OMB clearance on June 30,
2014.
The CHGME Support Reauthorization
Act of 2013 included a provision to
allow certain newly qualified children’s
hospitals to apply for CHGME Payment
Program funding. The CHGME Payment
Program application forms have been
revised to accommodate the new statute.
In addition, a payment question
included in the CHGME Payment
Program application forms has been
removed, since the participating
SUMMARY:
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
children’s hospitals are now required to
electronically communicate their
financial information to the Payment
Management System through the
Electronic Handbook.
The form changes are only applicable
to the HRSA 99–1 (also known as
Exhibit O (2)) and HRSA 99–5 forms.
All other hospital and auditor forms are
the same as currently approved. The
changes to the HRSA 99–1 and HRSA
99–5 forms require OMB approval and
are as follows:
1. HRSA 99–1: Add additional
description to Line 4.06 (both Page 2
and Page 2 Supplemental), 5.06 and
6.06. The current description is ‘‘FTE
adjusted cap.’’ The new description will
be ‘‘FTE adjusted cap or 2013 CHGME
Reauthorization cap due to Public Law
113–98.’’
2. HRSA 99–5: Remove Payment
Information question and check boxes,
applicable only to: (1) Hospitals which
have not previously participated in the
CHGME Payment Program, and (2)
hospitals in which financial institution
information has changed since
submission of its last application.
Need and Proposed Use of the
Information: Data on the number of FTE
residents trained are collected from
children’s hospitals applying for
CHGME Payment Program funding.
These data are used to determine the
amount of direct and indirect medical
education payments to be distributed to
participating children’s hospitals.
Indirect medical education payments
are derived from a formula that requires
the reporting of discharges, beds, and
case mix index information from
participating children’s hospitals. As
required by statute, the FTE resident
assessment shall determine any changes
to the FTE resident counts initially
reported to the CHGME Payment
Program.
Likely Respondents: The likely
respondents include the estimated 60
children’s hospitals that apply and
receive CHGME Payment Program
funding, as well as the 30 auditors
contracted by HRSA to perform the FTE
resident assessments of the children’s
hospitals participating in the CHGME
Payment Program. Children’s hospitals
applying for CHGME Payment Program
funding are required by the CHGME
Payment Program statute to submit data
on the number of FTE residents trained
in an annual application. Once funded
by the CHGME Payment Program, these
same children’s hospitals are required to
submit audited data on the number of
FTE residents trained during the federal
fiscal year to participate in the
reconciliation payment process.
Contracted auditors are requested by
E:\FR\FM\09DEN1.SGM
09DEN1
Agencies
[Federal Register Volume 81, Number 237 (Friday, December 9, 2016)]
[Notices]
[Pages 89113-89114]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-29499]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Council on Graduate Medical Education
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Notice of charter renewal.
-----------------------------------------------------------------------
SUMMARY: HHS is hereby giving notice that the Council on Graduate
Medical Education (COGME) has been renewed. The effective date of the
renewed charter is September 30, 2016.
FOR FURTHER INFORMATION CONTACT: Dr. Kennita Carter, Senior Advisor
and Designated Federal Official, Division of Medicine and Dentistry,
HRSA, HHS, 15M116, 5600 Fishers Lane, Rockville, MD 20857. Phone: (301)
945-3505; email: kcarter@hrsa.gov.
SUPPLEMENTARY INFORMATION: COGME is authorized by section 762 (42
U.S.C. 294o) of the Public Health Service Act,
[[Page 89114]]
as amended. Except where otherwise indicated, COGME is governed by
provisions of the Federal Advisory Committee Act (5 U.S.C. App. 2), as
amended, which sets forth standards for the formation and use of
advisory committees. In accordance with the Federal Advisory Committee
Act (FACA), COGME was initially chartered on September 30, 1996, and
has been renewed at appropriate intervals.
COGME provides advice to the Secretary of HHS (Secretary) on a
range of issues including: The supply and distribution of physicians in
the United States; current and future physician shortages or excesses;
issues relating to foreign medical school graduates; Federal policies
related to the previously listed topics, including policies concerning
changes in the financing of medical education training; and the
development of performance measures and longitudinal evaluation of
medical education programs. COGME's reports are submitted to the
Secretary and Chairmen and Ranking Members of the Senate Committee on
Health, Education, Labor, and Pensions and the House of Representatives
Committee on Energy and Commerce.
Renewal of the COGME charter authorizes the Committee to operate
until September 30, 2018.
A copy of the COGME charter is available on the COGME Web site at
https://www.hrsa.gov/advisorycommittees/bhpradvisory/cogme/. A
copy of the charter also can be obtained by accessing the FACA database
that is maintained by the Committee Management Secretariat under the
General Services Administration. The Web site address for the FACA
database is https://www.facadatabase.gov/.
Jason E. Bennett,
Director, Division of the Executive Secretariat.
[FR Doc. 2016-29499 Filed 12-8-16; 8:45 am]
BILLING CODE 4165-15-P